Global, Regional, and National Burden of Male Breast Cancer, 1990–2021: A Systematic Analysis for the Global Burden of Disease Study 2021

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2025-01-29 DOI:10.1002/cam4.70632

Long Wang, Ping Wen, Qing Shao, Dongping Jiang, Yulan Zhao, Xiaohua Zeng

{"title":"Global, Regional, and National Burden of Male Breast Cancer, 1990–2021: A Systematic Analysis for the Global Burden of Disease Study 2021","authors":"Long Wang, Ping Wen, Qing Shao, Dongping Jiang, Yulan Zhao, Xiaohua Zeng","doi":"10.1002/cam4.70632","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Male breast cancer (MBC) is rare and often treated using evidence from female breast cancer (BC) trials due to limited male participation. Previous estimates lacked global coverage and completeness. We aimed to quantify the global MBC burden from 1990 to 2021 and evaluate its current status and trends.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Based on the global burden of disease (GBD) database, we gathered and analyzed data on the incidence, death, and disability-adjusted life years (DALYs) of MBC while utilizing age-standardized rates (ASRs) as indicators for these measurements. Our study calculated the estimated annual percentage change (EAPC), aiming at measuring the average change in ASRs. Additionally, we evaluated the attributable risk factors (RFs) and trends of MBC across different regions and age groups worldwide.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In 2021, the global MBC age-standardized incidence rates (ASIR), age-standardized death rates (ASDR), and age-standardized DALY rates (ASDALY) per 100,000 persons were 0.941 (95% UI, 0.605–1.155), 0.335 (95% UI, 0.232–0.409), and 9.157 (95% UI, 6.116–11.423), respectively. In comparison to 1990, these rates have increased by 2.212 (95% UI, 2.047–2.378), 0.664 (95% UI, 0.562–0.767), and 0.853 (95% UI, 0.750–0.956) respectively. In Uganda 2021, the ASIR and ASDR of MBC were the highest at 4.541 (95% UI, 3.028–6.808) and 3.510 (95% UI, 2.301–5.195) per 100,000 persons, respectively. Moreover, the burden of MBC exhibited an increase with age. Globally, dietary risk was the most important attributable RF for MBC deaths, with a death percentage of 11.690% (95% UI, −0.003%–24.838%), followed by alcohol use and tobacco.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>From 1990 to 2021, the ASIR, ASDR, and ASDALY of MBC have shown significant disparities and an increasing trend. Committing to healthy lifestyle choices, such as decreasing tobacco and alcohol consumption and making positive changes to dietary habits, can assist in reducing MBC risk. The development and execution of robust and effective public health policies are crucial for alleviating the global disease burden.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 3","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11775920/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70632","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Male breast cancer (MBC) is rare and often treated using evidence from female breast cancer (BC) trials due to limited male participation. Previous estimates lacked global coverage and completeness. We aimed to quantify the global MBC burden from 1990 to 2021 and evaluate its current status and trends.

Methods

Based on the global burden of disease (GBD) database, we gathered and analyzed data on the incidence, death, and disability-adjusted life years (DALYs) of MBC while utilizing age-standardized rates (ASRs) as indicators for these measurements. Our study calculated the estimated annual percentage change (EAPC), aiming at measuring the average change in ASRs. Additionally, we evaluated the attributable risk factors (RFs) and trends of MBC across different regions and age groups worldwide.

Results

In 2021, the global MBC age-standardized incidence rates (ASIR), age-standardized death rates (ASDR), and age-standardized DALY rates (ASDALY) per 100,000 persons were 0.941 (95% UI, 0.605–1.155), 0.335 (95% UI, 0.232–0.409), and 9.157 (95% UI, 6.116–11.423), respectively. In comparison to 1990, these rates have increased by 2.212 (95% UI, 2.047–2.378), 0.664 (95% UI, 0.562–0.767), and 0.853 (95% UI, 0.750–0.956) respectively. In Uganda 2021, the ASIR and ASDR of MBC were the highest at 4.541 (95% UI, 3.028–6.808) and 3.510 (95% UI, 2.301–5.195) per 100,000 persons, respectively. Moreover, the burden of MBC exhibited an increase with age. Globally, dietary risk was the most important attributable RF for MBC deaths, with a death percentage of 11.690% (95% UI, −0.003%–24.838%), followed by alcohol use and tobacco.

Conclusion

From 1990 to 2021, the ASIR, ASDR, and ASDALY of MBC have shown significant disparities and an increasing trend. Committing to healthy lifestyle choices, such as decreasing tobacco and alcohol consumption and making positive changes to dietary habits, can assist in reducing MBC risk. The development and execution of robust and effective public health policies are crucial for alleviating the global disease burden.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.